Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA 2020 Novel Approval Count Rises To 53 At CDER, Plus 5 New CBER Biologics

Jan 01 2021

• By Bridget Silverman

fishing vessel with Pink Sheet Perspectives badge — While not a high-water mark, US FDA's 2020 approval total is still one for the history books • Source: Shutterstock

Related Content

Keeping Track: Incomplete Responses For Unusual Times; Qtrypta Is Latest CRL

Oct 31 2020

US FDA Reaffirms Commitment To Resuming Domestic Inspections As Industry Frustration Grows

Nov 27 2020

US FDA Picks Up The Pace Of Complete Response Letters Over June And July

Aug 05 2020

The US FDA’s Nifty Fifty

Dec 23 2020

Firms That Get Complete Response Letters Might Get Inspected By US FDA Six Months After Replies

Dec 23 2020

Keeping Track: Myovant, Almirall, MacroGenics Nab Novel Approvals; Novartis’ Inclisiran Delayed

Dec 22 2020

Related Companies

Gilead Sciences, Inc.

Novartis AG

BioMarin Pharmaceutical Inc.

Bristol Myers Squibb Company

Spectrum Pharmaceuticals, Inc.

Revance Therapeutics, Inc.

Additional Topics

United States Approvals Regulation Drug Review Pink Sheet Perspectives US FDA Performance Tracker Neurology Cancer BioPharmaceutical

More from Pink Sheet Perspectives

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window